1.85Open1.85Pre Close0 Volume2 Open Interest5.00Strike Price0.00Turnover221.19%IV21.89%PremiumOct 4, 2024Expiry Date0.62Intrinsic Value100Multiplier3DDays to Expiry1.23Extrinsic Value100Contract SizeAmericanOptions Type0.7556Delta0.2827Gamma7.03Leverage Ratio-0.0640Theta0.0003Rho5.31Eff Leverage0.0016Vega
Inovio Pharmaceuticals Stock Discussion
https://www.msn.com/en-us/health/other/bird-flu-pandemic-fears-skyrocket-as-us-identifies-first-cases-of-possible-human-to-human-transmission/ar-AA1rwhf5?ocid=BingNewsSerp
Inovio Receives Advanced Therapy Medicinal Product Certificate From European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate Ino-3107
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
No comment yet